In this episode, we dive in to the T'd Up T-cells region of RheumMadness 2025: the Innovation Invitational.  This is the first of a two-part conversation with the authors of the scouting reports ...

Infections are the primary cause of nonrelapse mortality among individuals who undergo chimeric antigen receptor T-cell therapy, according to study results.Unique CAR-T-specific side effects — s...

Background/Purpose: Chimeric antigen receptor (CAR)-T-cell therapies hold promise for systemic lupus erythematosus (SLE) but are critically limited by scalability and long-term safety (e.g., risk of t...

Background/Purpose: The autoreactive B cell compartment in systemic lupus erythematosus (SLE) is characterized by expansion of B cells expressing immunoglobulin heavy variable gene 4-34 (IGHV4-34) B c...

Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting ...